Skip to search formSkip to main contentSkip to account menu

Reverset

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dexelvucitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R.
2004
2004
5th Antiviral Drug Discovery and Development Summit.
The 5th Antiviral Drug Discovery and Development Summit provided an up-to-date snapshot of the ongoing developments in the area… 
2004
2004
New HIV Drug Class : ‘ Entry Inhibitors ’ Which Block HIV from Entering CD 4 Cell
IN THIS ISSUE: Tipranavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 HIV Entry Inhibitors… 
2003
2003
Potent Antiviral Effect of Reverset™ in HIV-1-Infected Adults following a Single Oral Dose
Reverset™ (2′,3′-didehydro-2′,3′-dideoxy-5-fluorocyti-dine, RVT) is a potent inhibitor of HIV-1 replication in cell culture, with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)